ZEB1 / DyLight 550 / OTI3G6
Product Details
| Description | Mouse ZEB1 antibody [DyLight 550] detects Human | |
|---|---|---|
| Conjugate | DyLight 550 | |
| Clone | OTI3G6 | |
| Target Species | Human | |
| Applications | WB, IHC | |
| Supplier | Novus Biologicals | |
| Catalog # | Sign in to view product details, citations, and spectra | |
| Size | ||
| Price | ||
| Antigen | ||
| Host | ||
| Isotype |
About ZEB1
This gene encodes a zinc finger transcription factor. The encoded protein likely plays a role in transcriptional repression of interleukin 2. Mutations in this gene have been associated with posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy. Alternatively spliced transcript variants encoding different isoforms have been described.[provided by RefSeq, Mar 2010]
This gene encodes a zinc finger transcription factor. The encoded protein likely plays a role in transcriptional repression of interleukin 2. Mutations in this gene have been associated with posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy. Alternatively spliced transcript variants encoding different isoforms have been described.[provided by RefSeq, Mar 2010]
About DyLight 550
DyLight™ 550 has an excitation peak at 562 nm and an emission peak at 576 nm and is spectrally similar to Alexa Fluor™ 546, Alexa Fluor™ 555, Cy3 and TRITC. DyLight™ 550 is most commonly used in flow cytometery and fluorescence microscopy applications.
DyLight™ 550 has an excitation peak at 562 nm and an emission peak at 576 nm and is spectrally similar to Alexa Fluor™ 546, Alexa Fluor™ 555, Cy3 and TRITC. DyLight™ 550 is most commonly used in flow cytometery and fluorescence microscopy applications.
Experiment Design Tools
Panel Builders
Looking to design a Microscopy or Flow Cytometry experiment?
Validation References
| Additional Sources |
|
|---|
Reviews & Ratings
| Reviews |
|---|
Looking for more options?
392 ZEB1 antibodies from over 23 suppliers available with over 40 conjugates.
